2024 PET Scan Radiopharmaceuticals 
AuntMinnie
MARCH 7, 2024
In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% year over year, according to the newly published IMV 2024 PET Market Summary Report. In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7%
AuntMinnie
OCTOBER 2, 2024
The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. PET scans reveal a key molecular driver of stress and addiction in people with alcohol use disorder. PET scans predict patient response to Pluvicto.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Imaging Technology
OCTOBER 21, 2024
tim.hodson Mon, 10/21/2024 - 10:17 Oct. 21, 2024 — Siemens Healthineers recently received Food and Drug Administration clearance for two new features in its syngo.PET Cortical Analysis software application that use positron emission tomography (PET) to measure protein deposits in the brain associated with Alzheimer’s disease.
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
AuntMinnie
JANUARY 19, 2024
Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PET imaging in some regions. Centers for Medicare and Medicaid Services (CMS), for example, did not cover amyloid PET scans outside of clinical trials for Medicare beneficiaries and only covered one scan per patient’s lifetime.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Expert insights. Personalized for you.
116 
Let's personalize your content